Delcath Systems Inc DCTH

$14.04 -0.60 (-4.10%)

Valuation

Market cap
487,174,000
Revenue TTM
$85,230,000
Net income TTM
$2,700,000
P/E (trailing)
1,464.00
P/E (forward)
—
Profit margin
3.17%
Debt to equity
0.00

Trading

Volume
427,300
Avg volume
345,832
Day's range
$13.91 – $15.24
Shares out
34,699,000
Stochastic %K
10%
Beta
0.60
Analysts
Strong Buy
Price target
$25.00

Price

Company profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO...

Show more

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Industry
Medical Devices
Sector
Healthcare
Phone
212 489 2100
Website
https://www.delcath.com
Address
566 Queensbury Avenue, Queensbury, United States

Latest news

Stocktwits

GioW Oct 31, 12:34 PM
$DCTH I think DCTH beats big time this quarter. We know that at the last conference call on Aug 6th they hadn’t seen any summer slowdown yet, because they said so. We also know there was an acceleration of treatments per center in Q2 to 1.8 treatments per center per month. At the same monthly run rate per center, we are looking at $30M US revenue plus European revenue of $1.5m that’s $31.5m for Q3, which is 55% revenue growth YOY. The street is at $25.84m That’s a headline beat of 22% and they’d have to raise FY guidance to $120M. The stock price should jump to over $18, unless the market is tanking. $14 is very cheap.
0 replies
GioW Oct 30, 11:25 PM
$DCTH predictions for November 9th revenues? Looking at the numbers of treatment centers open, if there was no summer slowdown this year we are well north of $30M, which would be a significant beat and a big jump c/w last year.
0 replies
brunoq14 Oct 30, 5:39 PM
$DCTH Apparently the market was not impressed by BlackRock taking a 6.3% position.
0 replies
prismmarketview Oct 29, 4:46 PM
October is National Liver Awareness and Liver Cancer Month. The American Liver Foundation estimates that 100 million Americans live with some form of liver disease. Altimmune ($ALT ) and Inventiva ($IVA ) are advancing MASH treatments, with Inventiva expecting Phase 3 topline results this quarter. Delcath ($DCTH ) delivers chemotherapy directly to the liver, while Aligos ($ALGS ) has a fully enrolled Phase 2 trial in hepatitis B. https://prismmarketview.com/national-liver-awareness-and-liver-cancer-month-four-companies-developing-treatments-for-mash-liver-tumors-and-hepatitis-b/
0 replies
brunoq14 Oct 28, 11:58 PM
$DCTH https://investors.delcath.com/node/19186/html. Schedule 13G/09/30/2026. BlackRock Portfolio Management 6.3% interest. 2.2.M shares
0 replies
GioW Oct 27, 11:07 PM
$DCTH this will fly once it clears 15 on the chart.
0 replies
mar99 Oct 27, 8:34 PM
$DCTH Looks like latest 13G from Blackrock shows increased holdings of Dcth July had 5.3% with 1,836,121 shares. Today’s filing shows 6.3% with 2,180,493 shares of DCTH
0 replies
brunoq14 Oct 27, 1:49 PM
$DCTH The day after earnings, November 10, Delcath will be presenting at the UBS Global Healthcare Conference. For this conference there will be a live and archived webcast. Possible new coverage?
0 replies